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Non-essential Metals in Chemical Biology
Paul J. Dyson*
Abstract: Metal ions and compounds are essential to life and many people routinely take them as food supple-
ments in the form of vitamin and mineral pills. Most non-essential metals are considered to be toxic, nevertheless, 
many are widely used in imaging, diagnostics and medicine. This short review provides an overview from selected 
examples of the on-going research within my laboratory that uses metal compounds to either understand bio-
logical processes or that exhibit therapeutic properties overcoming the limitations of existing chemotherapies.
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While life depends on essential metal ions 
to fulfil a wide and diverse range of func-
tions,[1] modern medicine utilizes a num-
ber of non-essential metal ions in a diverse 
range of applications including diagnostics, 
imaging and therapeutic applications.[2] 
Other non-essential metal compounds 
have been exploited in biochemistry and 
molecular biology for many years, such as 
ruthenium red that has been used as a tool 
to study specific cellular mechanisms but 
is limited as it interacts with a large num-
ber of proteins including ion channels.[3] 
Consequently we evaluated a series of flu-
orescent ruthenium tris(bipyridine) com-
plexes in which the bipyridine ligand is 
derivatised with substituents.[4] The com-
plexes were found to penetrate cells and 
accumulate in different locations depend-
ing upon the functional group attached to 
the bipyridine ligand. The most lipophilic 
complex, [Ru(4,4’-diethylamino-2,2’-
bipyridine)
3
], was found to adhere to the 
plasma membrane and could prove to be 
a useful staining agent in certain applica-
tions (Fig. 1). The nature of the ligands at-
tached to the ruthenium centre are critical 
in determining the localisation of the com-
pound in cells and a ruthenium polypyridyl 
complex was found to accumulate in the 
cell nucleus and can even be used to di-
rectly image the DNA structure in vitro.[5] 
Nevertheless, the metal does exert some 
influence, as shown from a study in which 
we derivatised a ruthenium(ii) complex 
with an organic ligand that overcomes 
multidrug resistance in certain tumours. 
Compared to the free organic molecule, 
uptake of the ruthenium complex into cells 
was considerably faster as is accumulation 
in the cell nucleus.[6] The ruthenium cen-
tre appears to be responsible for these ef-
fects – with initial uptake enhanced by the 
neutral ruthenium complex which is then 
hydrolysed inside the cell and becomes 
positively charged, facilitating accumula-
tion in the nucleus.
While the fluorescent properties of 
metal compounds emanating from the li-
gands attached to them are useful, most 
non-essential elements have unique, intrin-
sic properties such as distinct isotopic pat-
terns and spectroscopic handles that vastly 
expand their utility in a biological environ-
ment. For example, metals not present in 
living systems can be detected and distin-
guished from background elements by in-
ductively coupled plasma mass spectrom-
etry (ICP MS) at picomolar concentrations 
in cells.[7] We recently used ICP MS to 
establish the location of cisplatin and two 
ruthenium drugs in clinical trials in ovarian 
cancer cells.[8] Ovarian cancer cells both 
susceptible and resistant to cisplatin were 
used in the study and differences in cellu-
lar uptake, localization in the cell nucleus 
and mitochondria, and also their expulsion 
from the cells was established providing 
valuable information on drug resistance.
It is even possible to determine the 
precise biomolecular targets of these 
metal drugs by separation of the protein 
fractions by gel electrophoresis and sub-
sequent analysis of the gels by laser abla-
tion ICP MS, which identifies the specific 
proteins to which the metal binds – as-
suming covalent binding – following ex-
traction of the metal-containing protein 
band/spot and characterisation by con-
ventional proteomics methods.[9] Other 
chromatographic approaches have also 
been employed to achieve essentially the 
same task.[10] Moreover, since most metal 
compounds bind to their biomolecular tar-
gets via covalent bonds, determination of 
the precise binding site(s) is possible due 
to the unique and distinctive isotope pat-
terns of metals, using both bottom-up[11] 
and top-down[12] approaches to break the 
biomolecule into fragments allowing the 
part where the metal binds to be identified. 
Consequently, metal compounds represent 
ideal labels that can be detected at very low 
levels using various analytical techniques 
on different scales, i.e. from general lo-
calization within the cell to the interac-
tion with specific biomolecules including 
DNA, RNA and proteins, and ultimately to 
the exact binding site on the biomolecular 
Fig. 1. Confocal 
fluorescence 
microscopy showing 
accumulation of 
[Ru(4,4’-diethylamino-
2,2’-bipyridine)3] 
at the plasma 
membrane. The image 
on the left shows 
the fluorescence of 
the compound (red) 
and on the right the 
transmitted light.
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zymes and proteins are abundant and criti-
cal, and of high relevance for ruthenium 
compounds. In our own research we have 
developed a series of organoruthenium 
compounds, termed RAPTA, that display 
selective antimetastatic[16] and antiangio-
genic activity (Fig. 3).[17] 
Their mode of action is very different to 
that of cisplatin and other cytotoxic plati-
num agents and while both classes of com-
pound reach the cell nucleus the platinum 
compounds bind to many different DNA 
and histone sites within the nucleosome[18] 
whereas the RAPTA compounds show a 
strong preference for binding to the histone 
protein core.[19] This difference may be ap-
preciated from the ca. 200 KDa structure of 
the nucleosome core particle soaked with 
the various drugs – Fig. 4 shows binding of 
[Ru(η6-p-cymene)Cl
2
(pta)] (RAPTA-C) to 
the nucleosome core particle exclusively at 
the histone core.
The mechanism of action of RAPTA-C 
and other RAPTA compounds has been 
partly elucidated from a series of in vitro 
and in vivo experiments.[20] Treatment with 
RAPTA-C triggers G
2
/M phase arrest and 
apoptosis, associated with increased levels 
of p21 and p53 and reduced amounts of 
cyclin E, the release of cytochrome c and 
caspase-9 activation. However, the origin 
of the selectivity of the compound towards 
highly invasive and metastatic tumours is 
poorly understood.[21] Nevertheless, im-
provements on the efficacy of these com-
pounds have been attempted. For example, 
modification with ethacrynic acid, a glu-
tathione transferase inhibitor, markedly 
alters the anticancer properties of these 
compounds.[22] Since the RAPTA fam-
ily of compounds are investigational drug 
compounds we also modified cisplatin 
with ethacrynic acid for comparison (Fig. 
3).[23] It should be noted that in certain 
cancers, including solid metastases, there 
is a correlation between over-expression 
of glutathione transferases (GSTs), that 
catalyse the nucleophilic attack by reduced 
glutathione on cancer chemotherapeutic 
agents, which is part of a defence strategy 
to remove glutathione conjugates from 
the cell.[24] The structure of the most ef-
fective ruthenium-ethacrynate derivative, 
viz. [Ru(η6-phenylethacrynate)Cl
2
(pta)] 
co-crystallised with GST P1-1 (the human 
form of the enzyme associated with drug 
resistance) is shown in Fig. 5.[22b]
Remarkably, over time the RAPTA-
part of the structure (Ru-centre, arene and 
phosphine co-ligands) is cleaved from the 
ethacrynic acid group, the former being ex-
pelled from the GST and the latter remain-
ing behind, inhibiting the enzyme. This 
scission-elimination process was estab-
lished by several different techniques and 
appears to explain the overall mode of ac-
tion of the compound, involving apoptosis 
target. Fig. 2 provides an overview of the 
approach that we have developed to delin-
eate the fate of metal compounds, typically 
putative drug candidates, in cell culture. It 
should be noted that the same methodolo-
gy could be used to analyse biopsy samples 
such a tumour tissue from a patient follow-
ing a course of chemotherapy.
Our studies have focussed on platinum 
and ruthenium compounds in relation to 
their anticancer activity. Platinum com-
pounds are widely used in the clinic to 
treat a broad range of cancers[13] and two 
ruthenium drugs are currently undergoing 
clinical trials.[14] Ruthenium compounds 
appear to be better tolerated by the body, 
consequently having reduced side-effects, 
cautiously attributed to the similarity be-
tween ruthenium and iron – the body being 
well equipped to transport and store the lat-
ter.[15] Moreover, while DNA is a relevant 
target for metal drugs, interactions with en-
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Fig. 2. Methodology 
combining cell 
culture, gel 
electrophoresis, laser 
ablation inductively 
coupled plasma 
mass spectrometry 
and proteomics 
techniques that 
allows the proteins 
that interact with 
metal compounds 
to be identified. In 
the case of covalent 
modification, 
characteristic of 
metal-drugs, the 
binding sites can be 
identified.
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via a two-phase process. An initial surge 
of programmed cell death is followed by a 
more significant wave after several days.[25] 
Initial binding of the compound to GST 
P1-1 results in activation of the JNK apop-
tosis pathway. Subsequent release of the 
ruthenium fragment induces cytotoxic-
ity via a multi-mechanism pathway and 
also triggers cell protection mechanisms, 
e.g. expression of heat shock protein 70 
(possibly in response to inhibition of heat 
shock protein 90), that provides selectivity 
towards apoptosis-resistant cancer cells, 
thus protecting healthy cells. The struc-
ture of the Pt(iv)-ethacrynate compound, 
termed ethacraplatin, bound to GST P1-1 
has also been determined with the Pt ion 
reduced from Pt(iv) to Pt(ii), binding to 
the two cystine101 residues at the dimer 
interface with the two ethacrynic acid moi-
eties released from the metal bound at both 
H-sites.[26] A detailed experimental and 
theoretical mechanistic study of the bind-
ing process suggests that the compound 
initially migrates to the dimer interface, 
and subsequently is reduced and cleaved 
permitting the diffusion of the EA frag-
ments to the H-sites in the enzyme. Again, 
it would appear that ultimately the Pt(ii) 
ion is released, allowing it to exert its cy-
totoxic effect without being deactivated by 
the ethacrynic acid inhibited GST enzyme.
In summary, drug resistance is a recur-
ring problem in anticancer chemotherapy 
and is a complex problem involving many 
different cellular deactivation pathways. 
Current approaches to tackle this problem 
in the clinic tend to be based on the ap-
plication of combination therapies involv-
ing cocktails of drugs, radiotherapy and 
surgery. However, due to different rates of 
drug accumulation, compounds in which 
the ‘anticancer component’ is linked to 
the inhibitor such as those described here 
could prove advantageous in a clinical 
setting. In addition, there are very few 
selective drugs currently available for the 
treatment of metastasis, the main cause 
of mortality in patients diagnosed with 
cancer, and the ruthenium-based com-
pounds described here show promise in 
this respect, even though the reason for 
their selectivity is only partly understood. 
We have prepared and studied other com-
pounds related to those mentioned above, 
considering a number of different targeted 
and targeting approaches.[27] Moreover, 
since metals such as platinum, ruthenium, 
and many others are not naturally pres-
ent in living systems, and have powerful 
analytical handles, their biodistribution, 
cellular localisation, biomolecular targets 
and even specific binding sites can be es-
tablished. Consequently, metal compounds 
are not only used in clinical applications 
but for many years have been used to il-
luminate various biological functions and 
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Fig. 3. Structure 
of RAPTA-C (top 
left), [Ru(η6-
phenylethacrynate)
Cl2(pta)] (top right) 
cisplatin (bottom left) 
the Pt(iv) prodrug, 
ethacraplatin (bottom 
right).
Fig. 4. Location 
of RAPTA-C 
binding sites in the 
nucleosome on 
the histone core 
viewed down the 
pseudo-twofold axis 
of symmetry of the 
particle. The two 
145 nucleotide DNA 
strands are cyan 
and orange and the 
RAPTA-C Ru-ion is 
shown in magenta 
and RAPTA-C ligands 
in black (a). The 
main histone protein 
adduct formed 
with RAPTA-C, via 
substitution of the 
two chloride ligands, 
with two glutamate 
residues (b).
a)
b)
Fig. 5. Structure of [Ru(η6-phenylethacrynate)
Cl2(pta)] binding to human GST P1-1. The 
ruthenium(ii) ion binds to two cystine101 
residues via loss of the two chloride ligands 
at the dimer interface of the protein with the 
ethacrynic acid oriented towards the H-site 
(the site where the hydrophobic substrate 
usually binds). 
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are likely to be increasingly used as tools 
in chemical biology. 
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